At Advait, we are revolutionizing healthcare by bridging genetics and medicine through advanced pharmacogenomics services. Leveraging cutting-edge MALDI-based technology, renowned for its accuracy and rapid run time, we deliver precise genetic insights to help healthcare providers and researchers optimize drug therapies, predict drug responses, minimize trial-and-error in prescriptions and reduce adverse reactions. By integrating genetic insights into treatment planning, our services enable true precision medicine—delivering the right drug at the right dose, tailored to each individual.
Our PrecisionPath™ Panels
Advait offers targeted pharmacogenomic panels designed to address the most critical drug-gene interactions in clinical practice:
DPYD Panel
Identifies genetic variations in the DPYD gene, which are crucial for safe and effective use of fluoropyrimidine-based chemotherapies, such as 5-FU and capecitabine. This comprehensive screening helps prevent severe toxicity reactions in patients with reduced DPYD enzyme activity.
CYP2D6 Panel
Provides detailed genotype information for the CYP2D6 gene, influencing the metabolism of over 25% of commonly prescribed medications, including antidepressants, opioids, and beta-blockers. Results include identification of specific allelic variants and their impact on metabolizer status .
Book Your Test Now
PharmaScan 360™
Covers 16 key genes involved in major PGx drug metabolism pathways, providing genotype information for 85 Tier 1 and Tier 2 SNPs/INDELs recommended by leading pharmacogenetics societies. This comprehensive panel offers insights into the genetic basis of drug response for a wide range of therapeutic areas.
Why Choose Advait for PGx?
Focused on clinically actionable markers relevant to patient care.
Leveraging MALDI-based platform for high-throughput, accurate genotyping.
Panels aligned with guidelines from global pharmacogenetics organizations.
Timely reporting for critical clinical decisions.
